



WILSON SONSINI

ENTREPRENEUR
& INVESTOR
LIFE SCIENCES
SUMMIT 2026

MARCH 12-13, 2026

EVENT PROGRAM

HILTON SALT LAKE CENTER

PRESENTED BY



BIOUTAH

BYU

College of
Life Sciences

Technology
Transfer Office

ACCESS
WHOVA



Inspiring
innovation.

Preparing
biotech
leaders.

The future of biotechnology depends on leaders who are scientifically rigorous, ethically grounded, and ready to innovate from day one.

Working alongside faculty mentors on cutting-edge research, BYU Life Science students contribute to peer-reviewed publications, present at national conferences, engage in real-world problem solving, and ask questions to explore new possibilities.

They are trained in:

- Advanced laboratory techniques and instrumentation
- Data analytics and computational biology
- Interdisciplinary collaboration
- Regulatory and ethical frameworks in life sciences
- Clear scientific communication

BYU College of Life Sciences students are prepared to enter your organization ready to contribute.

Invite the next generation of biotech innovators to intern with your team.

URL

Internship Opportunity
Submission Form



<https://forms.office.com/r/BSu0kJe2xC>



WELCOME



BIOUTAH **BYU**

College of Life Sciences | Technology Transfer Office

WELCOME TO THE 2026 WILSON SONSINI ENTREPRENEUR & INVESTOR LIFE SCIENCES SUMMIT

On behalf of BioUtah and the Brigham Young University Technology Transfer Office and College of Life Sciences, we welcome you to the eleventh annual Entrepreneur & Investor Life Sciences Summit. We host this Summit for many reasons, including introducing investors to Utah's life sciences industry, showcasing exciting investable technologies developed in Utah, connecting companies and investors, providing content to assist early-stage companies, and fostering networking among various segments of our life sciences community—one of the fastest-growing in the country.

With the turmoil related to unrest in the Middle East and changes in federal government programming, this year's presentation on market perspectives by Monica DiCenso, head of Global Investment Opportunities Group for J.P. Morgan Private Bank, will be of particular interest. Our keynote speaker, Ann Somers Hogg, is the director of Healthcare Research at the Christensen Institute. She will be speaking about business model design, leadership approaches, customer orientation, and how disruption is not a strategy. It promises to be enlightening and informative.

This year's pitch competition follows the format instigated last year, with four groups of common-interest companies presenting to judges expert in that field. All companies that applied have been invited to post their information in our virtual Pitch Hall accessible through the Whova App. Check it out! And don't miss the afternoon tracks where important content will be presented on angel/seed funding, local venture capital, tech transfer activity, advice on launching a life sciences company, engineering a product vs platform, and how BYU's new medical school will incentivize research to positively impact global health.

We are excited about two new additions to this year's Summit. BYU is a new co-presenter and has initiated a student track. Dr. David Bearss, CEO of Halia Therapeutics, will be providing the keynote to the students at lunch in the main ballroom. All are invited to listen to his presentation. The other new addition is roundtables with experts on a variety of topics.

Attendees always say networking is the main highlight and reason to attend this event. We encourage you to use the Whova app, where all attendees are listed to communicate with others and even invite them to meet with you. Over 30 exhibitors will be on hand to share their products and services as well.

We are grateful for the generous support of our sponsors and exhibitors who make the Summit possible, especially our title sponsor Wilson Sonsini. We appreciate their partnership as well as that of all of our sponsors, most of whom have been supporting this event for many years. We thank the many investors who have taken the time to be here and learn more about the state's burgeoning innovation hub. Our goal for this Summit has always been to gather stakeholders to accelerate our industry's impact.

Enjoy the day!

Kelvyn Cullimore, Jr.
President & CEO
BioUtah

Mike Stark
Associate Dean, College of Life Sciences
Brigham Young University



EVENT SPONSORS

PRESENTED BY



BIOUTAH

BYU

College of Life Sciences

Technology Transfer Office

TITLE

WILSON SONSINI

VIP DINNER



DIAMOND



UTAH
INDUSTRY
PARTNERS

MORNING

J.P.Morgan

INVESTOR



STUDENT



LUNCH



FINANCE



ENTREPRENEUR



SKI DAY

Ballard Spahr
LLP

PRESENTING



CONTRIBUTING



DEPARTMENT of
ECONOMIC
DEVELOPMENT

Stephens

WI-FI



Governor's Office of
Economic Opportunity

PARTNER WITH UTAH'S FLAGSHIP LIFE SCIENCES INSTITUTION

Driving Innovation and Impact

The University of Utah offers flexible partnerships—sponsored research, joint ventures, and licensing agreements—translating innovations into real-world solutions. Our Technology Licensing Office connects you with cutting-edge research for efficient commercialization.



\$781.9M
RESEARCH FUNDING



530
DISCLOSURES



27
LICENSING DEALS



963,000+
SQ. FT. DEDICATED TO RESEARCH



43
U.S. PATENTS ISSUED



\$1B+
PARTNER REVENUE FROM LICENSED IP

**FY25 Metrics*

Key U of U Innovation Areas:



Bioengineering and Biomedical Engineering



Nanotechnology



Applied Artificial Intelligence & Machine Learning


And Much More!





VENUE LAYOUT

HILTON SALT LAKE CITY CENTER





WI-FI & WHOVA APP



WI-FI INSTRUCTIONS

Free public Wi-Fi is available compliments of the Governor's Office of Economic Opportunity.



Governor's Office of Economic Opportunity

Wi-Fi Network: "GOEO"

Password: "E&I2026!"



SUMMIT COMPANION APP: WHOVA

The E&I Summit uses the Whova platform to enrich your experience at the Summit. Whova allows you to learn about speakers and sponsors, engage with exhibitors, view our virtual Investor and Exhibit Halls, schedule meet ups with attendees, and more. Whova can be accessed via mobile app and web browser.

FOR MOBILE

Find the "Whova" app in the App Store (iPhone) or in Google Play (Android). After opening the app, sign in using the same email you used to register for the Summit, and then search for "Entrepreneur and Investor."

FOR DESKTOP

The Web/desktop version of Whova can be accessed at eilifsciencessummit.org by clicking the "Whova Access" link. Login to the Whova website using the email you used to register for the Summit.

POST-EVENT CONTENT ACCESS

Content can be accessed for up to three months after the Summit using the online app or the mobile app.

ACCESS WHOVA:



Governor's Office of Economic Opportunity
UTAH INNOVATION CENTER

Fueling Innovation, Funding Success

Nucleus Grow has helped over 500 Utah businesses secure \$375 million in non-dilutive R&D grants and contracts. Let us help turn your big ideas into funded realities.

Schedule a consultation:



**GOOD
IDEAS
NEED
A
PLACE
TO
INCUBATE.**



COMMERCIAL REAL ESTATE
DEVELOPMENT AND INVESTMENT



MORNING SESSION

MARCH 12, 2026
HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

SESSION SPONSOR

J.P.Morgan

LOCATION: MAIN BALLROOM

7:30 AM	Networking, Continental Breakfast	
8:30 AM	Welcome & Opening Remarks	Kelvyn Cullimore, President & CEO, BioUtah Laura Bridgewater, Dean, Brigham Young University College of Life Sciences Congressman Michael Kennedy (R-UT), United States House of Representatives
8:45 AM	Lessons Learned in Building a Life Sciences Company	Farah Gerdes, Partner, Wilson Sonsini [Moderator] Paul Perreault, Former CEO, CSL Limited Greg Critchfield, CEO, RefloDX Travis Sessions, CEO, Biomerics Zhenya Lindgardt, President & CEO, Sera Prognostics
9:30 AM	Investing in Life Sciences Companies: How the VC Landscape is Changing	Alison Johnson, Partner, Wilson Sonsini [Moderator] Frank Langston, Investor, Thiel Capital - Bio Fund Zachary Betts, CEO & Founder, Zandia Ventures Lu Han, Partner, Lumira Ventures Kirsten Horning, Partner, PL Capital
10:15 AM	Break	
10:30 AM	KEYNOTE: Market Perspectives for 2026	Monica DiCenso, Head of Global Investment Opportunities Group, J.P. Morgan
11:15 AM	KEYNOTE: Disruption Isn't a Strategy: How to Build Innovations that Win	Ann Somers Hogg, Director, Healthcare Research, The Clayton Christensen Institute
12:00 PM	Networking Lunch	<p>LUNCH SPONSOR</p> 



INVESTOR TRACK

MARCH 12, 2026

HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

TRACK SPONSOR



LOCATION: MAIN BALLROOM		HOST: ADAM STEVENS, BYU
SHARK TANK GROUP 1: THERAPEUTICS/PHARMACEUTICALS		JUDGES:
1:00 PM	<ol style="list-style-type: none"> 1. Azunic AI, Jerry Henley, CEO 2. Numiera, Izi Stoll, Founder and CEO 3. Glafabra, Chris Hopkins, CEO 	<p>Craig Jeppson, Epic Ventures Matt Dormer, Managing Dir., Health & Life Sciences, Stephens Julia Gregory, Chair & CEO, Isometry Advisors</p>
SHARK TANK GROUP 2: MED DEVICE & DIAGNOSTICS SERIES A		JUDGES:
1:50 PM	<ol style="list-style-type: none"> 1. Path Fertility, Andy Olson, CEO 2. Microvascular Therapeutics, Emmanuelle Meuillet, PhD, CSO 3. Purgo Scientific, Nicholas Ashton, CTO 	<p>Chris Cooley, Managing Director, Stephens Jolene Anderson, Managing Director, VectorPoint Ventures Jay Muse, CEO, Piper Access</p>
SHARK TANK GROUP 3: MED DEVICE & DIAGNOSTICS		JUDGES:
2:40 PM	<ol style="list-style-type: none"> 1. Freyya, Gabriele Niederauer, CEO & Co-founder 2. Bloom Surgical, Jacob Sheffield, CEO 3. DigiBeat Health, Clifford Steele, CEO 	<p>Branden Rosenhan MD, Founding Partner, MedMountain Ventures Mark Paul, Executive Director, Center for Medical Innovation, Univ. of Utah Zachary Betts, CEO & Founder, Zandia Ventures</p>
SHARK TANK GROUP 4: DIGITAL HEALTH / BIOTECH		JUDGES:
3:30 PM	<ol style="list-style-type: none"> 1. Intactis Bio Corp, Daniel Rodriguez-Granrose, Founder & CEO 2. Myxtek Bio, Christian Iverson, Co-founder 3. UV Sense, Kristina Schiffman, Founder & CEO 	<p>Tina Marriott, Founder/Principal, Lindrow Dani Goff, Program Director, Intermountain Ventures Gabi Tellez, Investor, SpringTide Ventures</p>
4:20 PM	Break	
4:45 PM	Announcement of Shark Tank Winners	



ENTREPRENEUR/FINANCE TRACKS

MARCH 12, 2026

HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

TRACK SPONSOR



ENTREPRENEUR TRACK

LOCATION: ALPINE ROOM

HOST: ALISON JOHNSON, WILSON SONSONI

1:00 PM	What You May Not Know About Launching a Life Sciences Company	Matt Meyer , Chief Business Advisor, Wilson Sonsini [Moderator] Ann Somers Hogg , Director, Healthcare Research, The Clayton Christensen Institute Curtis Sprouse , CEO/President, Institute for Biomedical Entrepreneurship (IBE) & EurekaConnect Ryan Rust , Senior Director, Business Development, Eli Lilly
1:40 PM	Universities as Innovators: Perspectives from the Tech Transfer Offices	Dave Brown , Director, BYU Tech Transfer [Moderator] Jason Young , Director of Commercialization, University of Utah Technology Licensing Office Jeri Hansen , Exec. Director for Research, Innovation & Impact, Utah State University Brad Baugh , Assoc. Gen. Counsel & Director, Utah Valley University Office of IP & Technology Transfer
2:10 PM	How the BYU School of Medicine Can Inspire Innovation and Research	Michael Stark , PhD, Associate Dean, BYU College of Life Sciences [Moderator] Mark Ott , MD, Dean, BYU School of Medicine Brandon Webb , MD, Assoc. Dean of Research, BYU School of Medicine
2:40 PM	Break	

TRACK SPONSOR



FINANCE & LEGAL TRACK

LOCATION: ALPINE ROOM

2:50 PM	Platform or Product? Engineering Optionality in a Volatile Biotech Market	Sara Patak , Partner, Wilson Sonsini [Moderator] Kapil Sharma , CEO, Vira Regen Rachel Jones , Chief Product Officer, VedaBio Ryan Watts , PhD, CEO, Denali Therapeutics
3:25 PM	Seed Fund Investor Panel	Jenny Barba , Managing Partner & Co-Founder, Features Capital [Moderator] Tomi Smith , Ecosystem Venture Partner/LP of Fund, Northwest Angel Fund Kristin Wihera , Director of Fund Operations, Nucleus Fund Bob Mitchell , Founder & Chairman, RDM Enterprises, LLC
4:10 PM	Yes, There is Venture Capital in Utah	Ryan Morley , Partner, SpringTide [Moderator] Luke Larsen , Vice President, Wasatch Health Branden Rosenhan , MD, Founding Partner, MedMountain Ventures Jack Boren , Managing Partner, Epic Ventures/University of Utah Ventures
4:45 PM	Announcement of Shark Tank Winners (Main Ballroom)	



BIOHIVE STUDENT TRACK

MARCH 12, 2026

HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

TRACK SPONSOR



LOCATION: CANYON ROOM B

HOST: ANDY ROBERTSON, BIOHIVE

12:00 PM	LUNCH KEYNOTE: An Entrepreneur's Journey [Main Ballroom]	David Bearss, PhD, CEO, Halia Therapeutics
1:00 PM	The Funding Landscape Explained (Without the Jargon)	Anh Hoang-Lindsay, CEO, Jana Care Ryan Morley, Partner, SpringTide Taylor Nadauld, Professor of Finance, BYU Marriott School of Business
1:45 PM	Student Engagement with Utah's Biotech Industry	Andy Robertson, Executive Director, BioHive [Moderator] Bryce Nelson, Coop. Education Program Manager, Talent Ready Utah Mark Paul, Executive Director, University of Utah Center for Medical Innovation Cindy Dunkle, Chief People Officer, Denali Therapeutics
2:15 PM	From Lab Bench to Startup: What Students Need to Know	Tim Jenkins, PhD, Associate Professor, BYU [Moderator] Chad Pollard, CEO, Renew Biotechnologies Brad Randall, Managing Partner, Union Capital Partners



ROUNDTABLES

MARCH 12, 2026

HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

NEW TO THE 2026 E&I SUMMIT

Our expert-led roundtables help life sciences companies anticipate challenges, avoid pitfalls, and maximize innovation. Open to all attendees (no appointment required), these interactive small-group sessions span three themed tracks and foster candid conversation and practical insights. **Discussions run every 30 minutes from 1:00-2:30.**

OPERATIONS SECTION		LOCATION: CANYON ROOM C		
START TIMES:	1:00 PM	1:30 PM	2:00 PM	
	IT Strategy with Musa Technology Partners & Binary Solutions	For companies at any stage: Explore IT strategies for growth—from secure, scalable infrastructure & cybersecurity to regulatory readiness and long-term planning	Justin Rusko, Musa Technology Partners Steven Fredericks, Binary Solutions	
	Using AI Inside Startups: Where it Helps, Surprises, & Creates Risks	Explore where & how AI tools are working, unexpected efficiency gains, emerging risks, & practical governance approaches that don't slow teams down.	Meredith Krannich, Wilson Sonsini	
COMMUNICATIONS SECTION		LOCATION: CANYON ROOM A		
START TIMES:	1:00 PM	1:30 PM	2:00 PM	
	Best Practices for Pitching to Investors	Experienced advisors will cover investor types, effective outreach, crafting a compelling pitch deck, and confidently handling tough investor questions.	Matt Brown, Wilson Sonsini	
	Investor Relations	Join an interactive roundtable on investor relations, featuring practical strategies to communicate your value in ways that resonate and stick.	Chelli Miller, Content Carnivores	



ROUNDTABLES

MARCH 12, 2026

HILTON SALT LAKE CITY CENTER

TITLE SPONSOR

**WILSON
SONSINI**

NON-DILUTIVE FUNDING SECTION		LOCATION: WASATCH ROOM	
START TIMES:	1:00 PM	1:30 PM	2:00 PM
	Contracting with DOD	Defense agencies are seeking to collaborate with biotech companies to transition cutting-edge technology for national defense & security. Learn about federal partnership opportunities.	Chuck Spence, APEX Accelerators
	Securing Non-Dilutive Government Funding	Discover how to navigate federal grants & position your company for success with practical insight into accessing critical non-dilutive capital.	Aditya Girish, G2G Consulting
	Funding Options Available Through Nucleus Institute	Nucleus Grow advises companies on securing non-dilutive SBIR/STTR grants. Nucleus Fund provides early-stage capital for companies with an affiliation to a Utah-based university.	Linda Cabrales, Nucleus Grow Kristin Wihera, Nucleus Fund

THANKS TO OUR ENTREPRENEUR TRACK SPONSOR:





SKI DAY

MARCH 13, 2026

TITLE SPONSOR
**WILSON
SONSINI**



9320 S. CLIFF LODGE DR.
SNOWBIRD, UT 84092

SKI DAY SPONSOR

Ballard Spahr
LLP

SKI DAY SCHEDULE

8:00 AM	Continental Breakfast	Superior Room, Cliff Lodge 9320 South Cliff Lodge Dr. Snowbird, UT 84092
9:00 AM	Skiing	
12:00 PM	Luncheon	Superior Room, Cliff Lodge 9320 South Cliff Lodge Dr. Snowbird, UT 84092
1:00 PM	Skiing (Ending at 4:00 PM)	

LIFT TICKETS

Lift tickets are available for purchase using the QR code.





BYU BRIGHAM YOUNG UNIVERSITY

Who We Are

We aim to benefit society by moving BYU inventions into the marketplace.

Our processes (from disclosure to deal) are:

- Fast,
- Simple, and
- Market-Friendly.

Unlike most universities, we often sell technologies outright (as opposed to licensing).

And BYU's students and faculty members are unusually entrepreneurial.

Engage with BYU Technology Transfer

Contact us at 801-422-6266

Connect with our Life Sciences leader, Adam Stevens, at adam_stevens@byu.edu

And Explore available technologies at techtransfer.byu.edu



Student Innovator Spotlight Carter Helquist

BYU undergraduate Carter Helquist transformed his cell biology research into Easey Skincare — a company delivering science-backed products using natural ingredients.

Driven by a mission to reduce suffering and help people feel confident in their skin, Helquist combined scientific rigor with compassionate innovation.

Working closely with BYU Technology Transfer, he succeeded at bringing a lab concept to market in twelve months.

Easey's products include Healing Cream and Acne Toning Mist.

See the whole story on YouTube:





SUMMIT PARTICIPANTS

TITLE SPONSOR

**WILSON
SONSINI**



JOLENE ANDERSON
MANAGING DIRECTOR,
VECTORPOINT VENTURES

Jolene Anderson is the managing director for VectorPoint Ventures, and has been an investor or advisor for seed and early stage impact companies for over two decades. She is a current Board member for Kinect Capital.org, the Evergreen Bioscience Innovation Cluster, co-chair ACA Impact Committee, co-chair for Keiretsu Forum Northwest Life Science Screening Committee, and Scientific Advisory Board chair for EndBrainCancer.org.



NICHOLAS ASHTON
CHIEF TECHNOLOGY OFFICER,
PURGO SCIENTIFIC

Nic Ashton is an assistant professor of Orthopaedics at the University of Utah and co-founder/CTO of Purgo Scientific. A biomedical engineer specializing in anti-biofilm technologies and intra-wound therapeutic delivery, Nic is an inventor on multiple patents including the Purgo Pouch. His postdoctoral work led to this refillable antimicrobial device earning FDA Breakthrough Device Designation. He is now spearheading the technology's transition into pivotal human trials, aiming to transform the management of complex long bone fracture-related infections and set a new standard in orthopedic care.



JENNY BARBA
MANAGING PARTNER,
CO-FOUNDER
FEATURES CAPITAL

Jenny Barba, co-founder and managing partner of Features Capital, is a venture investor and board member with over twenty-five years of experience financing the growth of medical device and healthcare technology innovation. Jenny has executed over \$4B in capital transactions across thirty lead-managed public and private equity offerings, M&A, and alternative investments. Jenny specializes in deal sourcing, portfolio construction, harvesting growth and building management teams in medical technology companies across all stages of development and a broad spectrum of diseases. Jenny has a successful track record fundraising for shareholder value creation, and strategic planning for corporate development, market expansion, commercialization growth and exits.



BRADLEY BAUGH
ASSOCIATE GENERAL
COUNSEL & DIRECTOR,
UTAH VALLEY UNIVERSITY
OFFICE OF IP & TECHNOLOGY
TRANSFER

Bradley Baugh is associate general counsel and director of the Office of Intellectual Property & Technology Transfer at Utah Valley University. A registered U.S. patent attorney with more than 25 years of experience, he has built and managed global patent portfolios, with particular expertise in high-tech inventions. Prior to joining UVU, he was a founding partner of a Silicon Valley-based IP firm, prosecuting hundreds of patents and advising technology companies and startups on strategy, licensing, and IP monetization. Bradley has taught Patent Law and Prosecution as an adjunct professor and regularly speaks on patent law and emerging technology issues.



DAVID BEARSS, PHD
CHIEF EXECUTIVE OFFICER,
HALIA THERAPEUTICS

Dr. David J. Bearss is a pioneering entrepreneur and drug development leader with more than two decades of experience translating breakthrough science into innovative medicines. An industry recognized expert in small-molecule drug discovery and genetic model systems, Dr. Bearss has built a career at the intersection of discovery biology, translational research, and precision medicine. His work has been particularly influential in leveraging genetic markers to predict drug sensitivity and guide clinical development strategies. Dr. Bearss currently serves as chief executive officer of Halia Therapeutics, a role he has held since March 2022, after serving as the company's chief scientific officer from January 2021. He is also a co-founder of Biolexis Therapeutics, established in November 2021, where he continues to guide the development of novel therapies for metabolic and inflammatory diseases.



ZACHARY BETTS
FOUNDER GENERAL PARTNER,
ZANDIA VENTURES

VC Family Office General Partner Investor, board member, and Advisor focused on seed to growth stage startups in healthcare, medical device, and AI technologies delivering innovation and sustainability impact to human and planet life.

SAVE THE DATE: **APRIL 16, 2026**



Utah's annual celebration of life sciences & healthcare innovation.

Come connect with Utah's leading minds, disruptors, experts and some of the most influential individuals in the life sciences and healthcare innovation industry.

LEARN MORE & REGISTER AT [BIOHIVE.COM/BIOHIVELIVE/](https://biohive.com/biohivelive/)



JACK BOREN
MANAGING PARTNER,
EPIC VENTURES / UNIVERSITY
OF UTAH VENTURES

Jack Boren is a managing partner at Epic Ventures, which manages University of Utah Ventures, Zions SBIC, LLC and the Epic Ventures Funds. Epic has been building category-defining healthcare and biotech businesses in the Mountain West for over 30 years.



MATTHEW BROWN
SR. DIRECTOR,
BUSINESS ADVISORY,
WILSON SONSINI

Matthew G. Brown is senior director for Life Sciences Business Advisory at Wilson Sonsini Goodrich & Rosati. Based in San Diego, his practice focuses on advising early-stage life sciences companies with capital raises and strategic business development initiatives. Matthew is an experienced executive and attorney who has held diverse roles of increasing responsibility across a wide range of private and public life sciences companies in the research tool, in vitro diagnostic, therapeutic, and therapeutic-enabling space including Genentech, Millipore Sigma, and Becton Dickinson & Company. His contributions span the continuum of strategic business development activities, from search and evaluation through alliance and program management.



LAURA BRIDGEWATER, PHD
DEAN, COLLEGE OF LIFE
SCIENCES
BRIGHAM YOUNG UNIVERSITY

Dr. Laura C. Bridgewater is dean of BYU's College of Life Sciences, which launches hundreds of students into medical and research careers each year. She earned her PhD at the George Washington University in Washington, D.C. and was a postdoctoral fellow at the M.D. Anderson Cancer Center in Houston. She has taught molecular biology to thousands of students and mentored nearly 200 students in her research lab, studying the regulation of gene expression and the gut microbiota's contributions to metabolic health disorders. She served as a department chair, associate dean, and associate academic vice president at BYU prior to becoming dean in 2022.



LINDA CABRALES
DIRECTOR, NUCLEUS GROW,
NUCLEUS INSTITUTE

Linda Cabrales is the director of Nucleus Grow at the Nucleus Institute. She works with entrepreneurs and researchers in their journey to develop and advance innovative technologies and supports businesses throughout the state to access non-dilutive funding. She values meeting with entrepreneurs and companies to strategize on their next move to advance their company and products, sharing her knowledge and enthusiasm for Utah's vibrant ecosystem.



DAVID BROWN
DIRECTOR, TECH TRANSFER,
BRIGHAM YOUNG UNIVERSITY

Dave earned his law degree at Georgetown University. He then practiced law with the firm of Spencer Fane Britt & Browne, in its St. Louis office. After six years of law firm practice, he returned to BYU to earn an MBA in Finance. For the past 15 years, he has worked for BYU. He became Director in 2023.



CHRIS COOLEY
MANAGING DIRECTOR,
STEPHENS

Chris has over 30 years of healthcare industry experience having begun his career in equity research covering healthcare services, healthcare information technology and medical devices and hospital supplies. During his tenure in equity research, Chris was ranked by the *Wall Street Journal*, the *Financial Times* and *StarMine* and was a speaker at multiple industry events and conferences. Chris joined Stephens in 2010 to lead equity research coverage of the Medical Device and Hospital Supply Sector and transitioned to Investment Banking in 2022 to head Stephens' ECM origination efforts in Health and Life Sciences.



GREG CRITCHFIELD, MD
CHAIR & CEO,
REFLODX, INC.

Greg Critchfield is chair and CEO of RefloDx, Inc. Greg's education includes a BS in microbiology from BYU, an MD from the University of Utah, and an MS in Biophysical Sciences from the University of Minnesota. His career spans faculty appointments (Minnesota, Wayne State, Duke); director of Clinical Pathology at Intermountain Healthcare; chief medical & science officer at Quest Diagnostics; president of Myriad Genetic Labs—creating a global leader in molecular diagnostics; chairman and CEO of Sera Prognostics, raising over \$300M through its 2021 IPO – serving on its board; and director of over 10 life science boards – overseeing public & private exits. Received the 2021 BioUtah Entrepreneur of the Year and the 2024 Utah Governor's Medal for Science and Technology/Industry.



SPARC Health is a startup platform for advice, resources, and community, supporting early-stage life science and health technology companies in Utah.

Through cohort-based programming, educational events, and mentor engagement, SPARC Health helps founders navigate key challenges across company formation, innovation, and growth.

Salt Lake City, Utah




KELVYN CULLIMORE
PRESIDENT & CEO,
BIOUTAH

Kelvyn Cullimore Jr. was named president & CEO of BioUtah, the state trade association for life sciences companies in Utah, in October 2018. Mr. Cullimore is a member of the board or on the advisory board for the World Trade Center Utah, Center for Medical Innovation at the University of Utah, BYU's Life Sciences Leadership Council, College of Science, Engineering and Technology at Utah Tech University. From 1992 to 2018 Mr. Cullimore was the president & CEO of Dynatronics Corporation, a leading manufacturer of physical therapy devices and products. Dynatronics, previously a publicly traded company, was originally founded by Mr. Cullimore and his father in 1979. He also served on the board of the Medical Device Manufacturers Association from 2003–2016. Mr. Cullimore was elected the first Mayor of Cottonwood Heights, UT, in November 2004 and served in that capacity until January 2018. He graduated cum laude from Brigham Young University in 1980 with a degree in Financial and Estate Planning.



MONICA DiCENSO
HEAD OF GLOBAL INVESTMENT
OPPORTUNITIES GROUP,
J.P. MORGAN

Monica DiCenso is a managing director and head of the Global Investment Opportunities (GIO) Group at J.P. Morgan Private Bank. As a senior leader of the firm, Monica sets the strategic direction for a team of 60+ Investors who advise the firm's largest and most sophisticated clients, including ultra-high-net-worth individuals and family offices. GIO is a specialized team drawn from the intellectual strength of J.P. Morgan, designed to provide cross-asset solutions to a global client base and offer institutional-caliber coverage. Throughout two decades immersed financial markets through various economic cycles, Monica has earned a reputation in the professional community as a specialist in this space. She has been featured on CNBC, *Bloomberg* and in various newspapers/trade publications discussing her views on financial markets. Monica's background comprises both the institutional lens of investment banking and exposure to the breadth of wealth management resources at the Private Bank.

As one of the nation's fastest growing life sciences and biotech communities, Salt Lake City is emerging as a world-class hub for innovation. With a bold vision and transformative ideas, we are paving the way for breakthroughs that will shape the future.

TECHLAKECITY.SLC.GOV



MATT DORMER
MANAGING DIRECTOR,
HEALTH & LIFE SCIENCES
INVESTMENT BANKING,
STEPHENS, INC.

Matt Dormer is a managing director that leads the Health & Life Sciences Investment Banking Group at Stephens Inc., a family-owned financial services firm founded in 1933. Matt has over 25 years of experience on Wall Street covering the biotechnology and life sciences industry as an equity research analyst and investment banker. Prior to his career on Wall Street he was a scientist focused in mRNA technologies. He earned a BS in Biology from Davidson College and an MBA in Finance from Northeastern University. His expertise includes advising clients on strategic transactions, mergers and acquisitions, and capital raises in the health & life sciences sector. In his free time he enjoys skiing and fly-fishing with his family and friends.



CINDY DUNKLE
CHIEF PEOPLE OFFICER,
DENALI THERAPEUTICS

Cindy Dunkle is chief people officer at Denali Therapeutics, where she leads people strategy, human resources, talent management, operations, and global facilities including environmental health and safety to support the company's mission and growth. At Denali, she has been instrumental in shaping a people-centered culture that attracts and retains top talent and aligns organizational development with business objectives. Cindy's career spans over 30 years in life sciences, with prior leadership roles at Genentech, Adverum, and other biotechnology organizations. She also serves on industry boards supporting the broader biotech ecosystem.



STEVEN FREDERICK
FOUNDER,
BINARY SOLUTIONS LLC

Steve is an information technology professional focused on IT infrastructure solutions to meet business needs and align with strategic goals of life science companies. 30 years of experience facilitating C-level technology strategy and roadmap discussions as well as first-hand technology implementation experience leading IT for high-growth biotech. A problem solver who is passionate about delivering business value and able to mobilize a broad IT vendor ecosystem to address complex challenges and the evolving needs of life science companies at all stages, from start-ups to established organizations.



FARAH GERDES
PARTNER,
WILSON SONSINI

Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, Farah helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, and development (including clinical development), and more.



ADITYA GIRISH, PHD
GOVERNMENT AFFAIRS
MANAGER & BIOSCIENCES
DIRECTOR,
G2G CONSULTING

Based in Washington, D.C., Aditya Girish is the government affairs manager & biosciences director at G2G Consulting, which has raised over \$612M in government funding since 2007. He works with a range of clients but focuses on biosciences R&D funding and health policy. Aditya publishes G2G's monthly *Government Bioscience Grants Report* that provides a comprehensive listing of federal life sciences funding opportunities and leads the accompanying webinars to highlight notable programs. Additionally, he publishes G2G's *Bio Bulletin* on policy developments impacting the biosciences community. A trained scientist, Aditya completed a PhD in biomedical engineering at Case Western Reserve University.



DANI GOFF
PARTNERSHIPS DIRECTOR,
INTERMOUNTAIN VENTURES

Dani Goff is the partnerships director for Intermountain Ventures, where she champions collaboration and practical innovation across the Intermountain Health ecosystem. She works at the front edge of partnership strategy—bringing together clinical, operational, and industry experts to marry early-stage ideas with real-world organizational impact. With a strong background in enterprise implementation science and project management, Dani’s focus is on cutting through complexity, aligning around shared priorities, and shepherding initiatives forward.




JULIA GREGORY
CEO,
ISOMETRY ADVISORS

Julia P. Gregory is chair and CEO of Isometry Advisors. She is a seasoned biotechnology executive with a proven track record for successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues and has extensive experience in recruiting outstanding management teams. As a biotechnology executive, she has raised more than \$2.5B for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies. She was CEO and board member of two biotechnology companies: ContraFect, and FivePrime Therapeutics (sold to Amgen), and was the EVP Corporate Development and CFO of Lexicon Pharmaceuticals, Inc. (LXRX). Ms. Gregory has twenty years of investment banking experience. Ms. Gregory is currently a director at Biohaven (BHVN), Nurix (NRIX) and Spinal Simplicity.



**Your Partner in Medical Device
Design, Development, and Manufacturing**



Since 2001, we have helped over six hundred customers to develop products and processes as they have pursued medical innovation. We are your partner in developing, prototyping, testing and producing the solutions that transform patient experiences and save lives.

Building the Future of MedTech Together™

www.pdvmedtech.com





Global Manufacturing

Assembly, Fulfillment,
Automation

Engineering Services

Injection & Silicone Molding

Tube Extrusion / FEP Expansion

Braided / Coiled Shaft

Printed Circuit Board
Assembly

Wire & Cable Extrusion

Sterilization Management

ATL-Medical.com

Cardiovascular • Electrophysiology • Electrosurgical • Imaging

Improving Lives Through Medical Device Innovation



SIMERDEEP SINGH GUPTA, PHD
FOUNDER & CEO,
ANZIVA PHARMACEUTICALS INC.
ALTERNATE PITCH PRESENTER

Dr. Simerdeep Singh Gupta is a pharmaceutical scientist and entrepreneur based in Salt Lake City, Utah. He is the founder and CEO of Anziva Pharmaceuticals, where he focuses on developing innovative transdermal and topical products for pain management. With a PhD in Industrial Pharmacy from St. John’s University and nearly a decade at Teva Pharmaceuticals, he specializes in formulation development, solid dispersions, and improving the performance of existing drugs. His work centers on creating differentiated pain therapies that address real patient needs through thoughtful formulation design and disciplined product development strategy.



JERI HANSEN
EXECUTIVE DIRECTOR,
RESEARCH
INNOVATION & IMPACT,
UTAH STATE UNIVERSITY

Jeri Hansen is the executive director of Research Innovation & Impact at Utah State University and has over 24 years of higher education experience, the majority of which has been as part of the research enterprise. She was the founding director of the Office of Proposal Development and led its expansion into a comprehensive Division of Research Development. In 2025, she began leading USU’s Technology Transfer group as part of a larger effort to support the research lifecycle by combining research development, industry partnership development, and technology transfer into the Division of Research Innovation & Impact.



LU HAN, PHD
PARTNER,
LUMIRA VENTURES

Dr. Lu Han is a partner at Lumira Ventures, a leading North American venture capital firm dedicated to creating and investing in innovative healthcare companies. Based in Vancouver, Lu brings over 12 years of experience at Lumira, where he focuses on identifying and supporting early-stage companies with groundbreaking therapies and technologies. Lu’s investment portfolio spans a wide range of therapeutic areas, including oncology, neuroscience, rare diseases, and inflammatory diseases. He currently serves on the Board of Directors for Deka Biosciences and AmacaThera, and as a board observer for Nocion Therapeutics, Iterion Therapeutics, and Transposon Therapeutics. He is also actively involved in Lumira’s investments in Alpha-9 Oncology, Axonis Therapeutics, Cadence Neuroscience, Navion, Thryv Therapeutics, HistoSonics, and Exact Imaging. Lu received his PhD in neuroscience from the University of Toronto followed by post-doctoral studies at the Hospital for Sick Children.



JERRY HENLEY
CEO,
AZUNIC AI

Jerry Henley is the CEO of Azunic AI and brings more than 17 years of experience at Amgen in biotech, corporate, and government accounts. He has spent a decade in private equity and venture capital and has served as managing director at The Connor Group and Utah Innovation Fund. Jerry also previously held roles as chief revenue officer at Tula Health and associate vice president at Utah Valley University, bringing a broad background in biotech leadership, investment, and higher education.





ANH HOANG-LINDSAY
CEO,
JANA CARE

Anh Hoang-Lindsay is the CEO of Jana Care, an early stage company focused on developing at-home blood testing for remote management of patients with chronic disease. Outside of Jana Care, Anh is the founder and a board director of Sofregen Medical Inc and a part-time faculty member at the Massachusetts Institute of Technology's (MIT) within the Catalyst LinQ program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.



ANN SOMERS HOGG
DIRECTOR, HEALTH CARE
RESEARCH,
THE CLAYTON CHRISTENSEN
INSTITUTE

Ann Somers is the director of health care research at the Christensen Institute where her research focuses on the structural pathways to improve health. This includes business model design, leadership approaches, customer orientation, and innovation strategy. Prior to joining the Institute, Ann Somers worked for Atrium Health (now Advocate Health), where she served as the AVP of Strategy and Transformation. She started her career consulting at Oliver Wyman, developing value-based care strategies for large insurers. She holds an MSPH in Health Policy and Management from UNC-Chapel Hill and a BS in Commerce from the University of Virginia.

Precision Medicine Through Inflammatory Science

Clinical-stage development with
Phase 2 programs

Halia Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies targeting inflammatory pathways across hematologic, metabolic, and neurodegenerative diseases, with Phase 2 clinical programs in myelodysplastic syndromes (MDS) and early-intervention Alzheimer's disease.





CHRIS HOPKINS
CEO,
GLAFABRA THERAPEUTICS

Chris is an experienced geneticist, biochemist, and entrepreneur. He guided the acquisition of Knudra Transgenics by InVivo Biosystems. He participated in raising over \$5M in funding from venture capital. Achieved more than \$7M in non-dilutive funding from SBIRs. Licensed CRISPR technology in 2014 shortly after it was invented. Inventor on 20+ patents. Created more than 40 service product lines. Cultivated a sales and marketing team that achieved more than \$10M in market revenue.



KIRSTEN HORNING
PARTNER,
PL CAPITAL NEURO

Kirsten Horning is a partner at PL Capital, where she is helping raise a \$300M neurotechnology fund focused on early-stage neurotech and neuro-AI investments. She is passionate about health technology and empowering individuals to take greater ownership of their wellness and care. Previously, Kirsten was managing director of the Republic Deal Room, providing accredited investors access to curated venture and SPV opportunities alongside top VC firms. She was also a Principal at XRC Ventures, investing in consumer and health-adjacent technologies with strategic partners including CVS Health.



CHRISTIAN IVERSON
CO-FOUNDER & CEO,
MYXTEK BIO

Christian Iverson is the co-founder and CEO of MyxTek Bio, jointly leading the company with co-founder Dr. Justin Jones to commercialize a recombinant hagfish protein biomaterials platform originally developed at Utah State University. Their technology enables next generation textiles, protective materials, and medical innovations. Christian brings over 15 years of experience translating

early stage science into commercial products, previously serving as executive director of Technology Transfer at Utah State University and co-founding Quansys Biosciences. He specializes in IP strategy, deep tech product development, and non dilutive funding. Christian holds an MBA and degrees in Biology and Business from Utah State University.



TIM JENKINS, PHD
ASSOCIATE PROFESSOR, BYU
CO-FOUNDER, RENEW
BIOTECHNOLOGIES

Tim Jenkins, PhD, is a professor in the Department of Cell Biology and Physiology at Brigham Young University, where he studies epigenetics, DNA methylation, and sequencing-based diagnostics while mentoring undergraduate researchers. He is also a co-founder of Renew Biotechnologies, a company focused on developing epigenetic tools to better measure biological aging and health. His work bridges academic discovery and biotechnology innovation to advance precision health and translational life-science research.



CRAIG JEPPESON
PRINCIPAL,
EPIC VENTURES

Craig Jeppson is a principal at EPIC Ventures, a Salt Lake City-based venture capital firm investing in Seed - Series A companies across healthcare, life sciences, and enterprise technology. He works closely with founders on strategy, fundraising, and scaling from early traction to growth. Earlier in his career, Craig worked at Toyota Motor North America, where he focused on Toyota/Lexus pricing strategy as well as product development and lifecycle management for the 4Runner. Before Toyota, Craig worked at Cumming Capital, a family office focused on late-stage private equity investments. Craig holds an MBA from the University of Texas McCombs School of Business, and is passionate about advancing the Intermountain West startup ecosystem.



ALISON JOHNSON
PARTNER,
WILSON SONSINI GOODRICH
& ROSATI

Alison G. Johnson is a corporate partner at Wilson Sonsini Goodrich & Rosati, where she focuses on the representation of emerging companies at all stages of growth, advising them on venture capital and other financings, mergers and acquisitions, private equity, and corporate governance matters. She also represents venture capital firms and angel investors. Alison's clients include both locally based and national companies across the country in a wide range of industries, including e-commerce, SaaS, biotechnology, and agtech. Prior to rejoining the firm in 2021, Alison served as Holland & Hart's firm-wide chair of the food and beverage and consumer products industry group. She joined that firm in 2010 and made partner in 2016. Alison began her legal career as a corporate associate in Wilson Sonsini's Palo Alto office. Alison is practicing virtually in Idaho, where she is licensed.



BRANDON JOHNSON
CEO, FOUNDER,
KYPHOLIFT
ALTERNATE PITCH PRESENTER

Brandon B. Johnson is the founder & CEO of KyphoLift, a medical device company expanding patient access to diagnostic imaging while reducing injury risk for clinical staff. With over 20 years in radiology, he identified a global clinical blind spot hidden inside MRI suites: manual patient lifting and improvised supports required to maintain positioning. Over seven years, he transformed that firsthand insight into KyphoLift, a standardized device-based solution now commercially deployed. Today, KyphoLift is FDA Class I and used in 80+ hospitals across the U.S., Canada, and Australia, with growing revenue and expanding distribution.





RACHEL JONES
CHIEF PRODUCT OFFICER,
VEDABIO

Rachel Jones has over 25 years of experience in molecular diagnostics and a proven record of building and scaling commercial organizations to deliver groundbreaking clinical solutions. As chief commercial officer at BioFire Diagnostics (now bioMérieux), she launched and expanded novel infectious disease platforms, establishing the company as the market leader in syndromic testing and guiding it to \$1B in revenue. Rachel’s expertise spans marketing, market access, reimbursement, and program management, with a consistent focus on driving adoption of transformative technologies. She is recognized for turning innovation into impact through strategic commercialization and business growth.



MIKE KENNEDY, MD
CONGRESSMAN (UT-03)

Dr. Kennedy earned his Bachelor of Science degree from Brigham Young University. He then pursued his medical degree at Michigan State University, becoming a dedicated family physician. His passion for helping others led him back to Brigham Young University to pursue a law degree, driven by a desire to better advocate for his patients and ensure they received the best care possible. Throughout his 33-year marriage to his wife, Katrina, Dr. Kennedy has raised eight children and now delights in his role as a grandfather to 10. With a lifelong commitment to service, Congressman Kennedy has served in both the Utah House and Senate while maintaining his family medicine practice. He was sworn into the United States House of Representatives in January 2025, where he is focused on restoring fiscal responsibility, securing America’s borders, and pushing back against federal overreach.

Stephens

With offices in the U.S. and Europe, we have a strong record of adding value to our clients. By virtue of being a family-owned investment banking company we offer unique perspective and objective advice.

Who We Serve



Private Companies



Public Companies



Family Offices



Financial Sponsors


Advisory Services We Offer



M&A Advisory



Equity Capital
Markets



Debt Capital
Markets



Capital Solutions

This communication has been prepared solely for informational purposes as of its stated date. It is not a solicitation, recommendation or offer to buy or sell any security and does not provide information on which an investment decision to purchase or sell any securities could be based. It does not purport to be a complete description of the securities, markets or developments referred to in this communication. Additional information is available upon request. "Stephens" (the company brand name) is a leading family-owned investment firm that includes Stephens Inc. (member NYSE/SIPC), Stephens Investment Management Group, LLC, Stephens Insurance, LLC, Stephens Capital Partners LLC and Stephens Europe Limited (Registered office: 12 Arthur Street, London, EC4R 9AB, Registered number 8817024), which is authorised and regulated by the Financial Conduct Authority. © 2026 Stephens.

The background of the slide features a blurred image of a laboratory setting. On the right side, a blue pipette is shown with a single drop of liquid hanging from its tip. Below the pipette, a multi-well microplate is visible, with several wells containing a red liquid. The overall color palette is dominated by blues, reds, and whites.

WILSON SONSINI

Partners in Discovery and Innovation

Wilson Sonsini represents life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships, and has one of the largest life sciences practices in the United States. For more than 60 years, our attorneys have represented trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today.



Life Sciences Leadership

The firm's life sciences practice features a multi-disciplinary team of attorneys, patent agents, and scientific advisors. We represent clients in a wide range of strategic and operational corporate areas and assist them with complex commercial and technology transactions driven by IP and innovation.

For more information, visit [wsgr.com](https://www.wsgr.com).

Attorney Advertising

Wilson Sonsini has 17 offices in technology and business hubs worldwide.
For more information, visit [wsgr.com/offices](https://www.wsgr.com/offices).



JESS KRANNICH
PARTNER,
WILSON SONSINI GOODRICH
& ROSATI

Jess M. Krannich is a litigation partner in the Salt Lake City office of Wilson Sonsini Goodrich & Rosati. Jess is a seasoned trial lawyer who leads significant intellectual property, unfair competition, patent, and general commercial matters for a wide range of clients in the technology, life sciences, medical device, consumer products, and financial services sectors. Many of his clients are major industry leaders in the Rocky Mountain West. Jess’ practice spans multiple types of complex commercial litigation, but focuses on competition disputes ranging from trade secret and restrictive covenant litigation to intellectual property disputes, unfair competition, and antitrust litigation. Jess has won nearly 20 jury and bench trials, arbitrations, and injunctive hearings. He has a strong record of obtaining early wins in large, complex cases through motion practice and strategic case development.



MEREDITH KRANNICH
EXECUTIVE ADVISOR,
WILSON SONSINI GOODRICH
& ROSATI

Meredith L. Krannich is an advisor in the Executive Advisory Program of Wilson Sonsini Goodrich & Rosati. Resident in the firm’s Salt Lake City office, she focuses on leveraging her nearly 20 years of experience in the life sciences sector as a lawyer and business executive to advise clients on a variety of legal operational and business matters. Prior to joining the firm, Meredith served as vice president and general counsel (North America operations) at bioMérieux, where she built and led diverse, talented, and collaborative in-house legal teams and advised on key strategic business initiatives, among other matters. Before assuming this role, she was vice president of legal affairs—and previously senior corporate counsel—at BioFire Diagnostics, which was acquired by bioMérieux in 2014. At BioFire Diagnostics, Meredith led the legal team in supporting all of the company’s operational areas, including by managing the compliance program; drafting and negotiating agreements for sales and marketing, distribution, and human resources.



ZIA L’ECUYER
CEO,
EYECSCREEN

Zia is the CEO of Eyescreen Inc., a pioneering biotech startup bridging the critical gap between preclinical drug development and human clinical trials. As a specialist in functional preservation and human eye tissues, Zia is developing a fee-for-service platform that enables pharmaceutical companies to test ocular therapies on functional human donor eyes, eliminating the translational failures inherent in animal models. Zia is actively building Eyescreen’s laboratory operations while positioning the company for pre-seed funding and it’s first pharmaceutical contracts.



FRANK LANGSTON
INVESTOR,
THIEL CAPITAL – BIO FUND

Frank Langston is an investor at Thiel Capital – Bio Fund, where he identifies, invests in, and supports high-impact biotech companies from seed to pre-IPO. The firm has backed industry leaders like Adimab, AbCellera Biologics (Nasdaq: ABCL), and Compass Pathways (Nasdaq: CMPS). A two-time founder and former executive at Ginkgo Bioworks’ Biosecurity division, Frank brings deep entrepreneurial insight to portfolio companies. He applies a first-principles approach and lateral thinking to help founders navigate biotech’s toughest challenges to outperform the status quo.



Patients are our life's work ...

At Edwards Lifesciences we are driven by a passion for patients and dedicated to improving lives.

It's about uncovering bold advancements, innovating structural heart and critical care technologies – and dreaming big to imagine brighter futures.

It all adds up to embracing the urgency to make a difference where it matters most. It's our mission for life ...

... and life is now.



Edwards, Edwards Lifesciences, the stylized E logo, and Life is Now are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-1612 v4.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Running a business is hard.
Doing it without the right expertise?

NEARLY IMPOSSIBLE.

Most businesses don't make it past five years.

Amplēo's experts in finance, HR, marketing, sales tax, and valuation help make sure yours does.



[ampleo.com](https://www.ampleo.com)

 **14,000**
Companies Nationwide



 **300**
Experts

 **5** Professional Services





LUKE LARSEN
VICE PRESIDENT,
WASATCH HEALTH

Luke is a vice president at Wasatch Health, where he leads the investment team and oversees thesis development, sourcing, market research, and due diligence activities. Before joining the firm, he held various roles in corporate development, finance, and market research, including positions at Koch Industries and Ford Motor Company. He graduated magna cum laude from Utah State University's Jon M. Huntsman School of Business.



ZHENYA LINDGARDT
CHIEF EXECUTIVE OFFICER,
SERA PROGNOSTICS

Zhenya Lindgardt is the CEO of Sera Prognostics, Inc., a maternal health biotech firm that's championing first-of-its-kind diagnostics to improve maternal health outcomes. Sera's most recent innovation includes the first-of-its-kind diagnostic that measures risk for premature birth using a woman's blood proteins as opposed to genetic-based testing, which delivers more accurate results and considers each woman's unique experience beyond inherited risk. Zhenya previously was a member of the executive leadership team at Uber Technologies, Inc. and senior partner and managing director at the Boston Consulting Group.



TINA MARRIOTT
FOUNDER & PRINCIPAL,
LINDROW

Tina Marriott is founder and principal of Lindrow, and former president & COO of Recursion, where she helped grow the company from Series B to a global, publicly traded leader in AI-driven drug discovery. She's held executive roles at Achaogen, Roche, and Genentech, and currently chairs the board of Revegenix. Tina has also served on higher education boards in Utah and Colorado, and was named a Distinguished Alumni by Colorado State University.



EMMANUELLE MEUILLET, PHD
CHIEF OPERATING
& SCIENTIFIC OFFICER,
MICROVASCULAR THERAPEUTICS

Emmanuelle J. Meillet is an accomplished scientist, inventor and entrepreneur. She obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She held an appointment as an associate professor at the University of Arizona. During her career in academia, she managed a team of up to 13 staff/personnel and up to \$10M non-diluting funds. She co-founded two biotech companies, PHusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules for oncology. Dr. Meillet joined MVT in 2018 and built the Research and Development program funded by non-diluting funds. She holds 5 issued U.S. patents. She actively manages the grants portfolio and directs all research and administrative aspects of them. She is involved in the electronic quality management system, manufacturing and all regulatory activities at the Company.



MATTHEW MEYER
CHIEF BUSINESS ADVISOR,
LIFE SCIENCES
BUSINESS ADVISORY,
WILSON SONSINI GOODRICH
& ROSATI

Matthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini Goodrich & Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues. Matthew is an experienced executive and attorney who has held diverse roles of increasing responsibility across a wide range of private and public biopharma, medtech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe, including Pfizer, Novartis, and CareDx. His leadership capabilities include delivery of strong commercial results, structuring and executing partnering transactions across the product life cycle, raising debt and equity capital in the private and public markets, and working with founders, management teams, and boards to address complex business issues.



CHELLI MILLER
PARTNER, VP CLIENT SERVICES,
CONTENT CARNIVORES

As life sciences lead partner and VP customer success at Content Carnivores, Chelli helps life sciences companies achieve their goals through innovative marketing and communications strategies. With nearly 20 years of experience, She has built a reputation for investor awareness campaigns – including campaigns for \$GOVX, \$KMPH, \$SLRX, and \$OCX. Chelli’s expertise spans investor relations, shareholder communications, corporate messaging, content marketing, media/PR, product commercialization, and strategic partnerships supporting emerging and growth-stage companies. Chelli specializes in clearly articulating a company’s value proposition to their targeted investors – turning complex science stories into compelling investment narratives.



BOB MITCHELL
FOUNDER & CHARIMAN,
RDM ENTERPRISES, LLC

Mr. Mitchell has led several medical device companies throughout his career, including Cook Medical, AngioDynamics, Align Technology, and Endologix. He is a founding partner of Utah-based FF20 Fund, a senior advisor to Hexagon VC, Mutiny Crew Inc. and TVM Capital Healthcare (Dubai). Previously, he co-founded Summit Life Science Partners. He has chaired and serves on several public and private company boards. For more than a decade, he has been a program director for the Charing Cross Symposium in London, U.K., and has been an invited lecturer and keynote speaker in more than a dozen countries.



RYAN MORLEY
PARTNER,
SPRINGTIDE

Ryan is a partner at SpringTide with experience driving innovation within health systems and in startup environments. Prior to SpringTide, Ryan helped pioneer population health models within the University of Utah Health delivery and payer arms. Ryan was the CFO of a digital health platform, TruClinic, and led its acquisition by InTouch Health, which was subsequently acquired by Teladoc. Ryan also served as the national deputy finance director for Senator Romney’s 2012 presidential campaign. Ryan earned a bachelor’s degree in accounting from Brigham Young University and an MBA from the Wharton School. He is a board director at OpenLoop, Troomi, Paterna Biosciences, and IgniteData. He is a board observer at Aegle Health Partners, Pinch, and Okadoc.

J.P.Morgan

Advancing breakthroughs, together

We are committed to fostering connections that drive investment and innovation in the life sciences industry.



© 2026 JPMorgan Chase & Co. All rights reserved.



UTAH INDUSTRY PARTNERS

HELPING MANUFACTURERS FIND SUCCESS

Utah Industry Partners' mission is to help Utah manufacturers maximize performance, profits, scale, and fuel the local economy. They do it through a no-cost business assessment, interactive training, hands-on partnerships, and by connecting manufacturers to custom-tailored resources they need to develop highly efficient teams and processes, turn business challenges into opportunities, and to maximize performance and profits.

Find custom-tailored solutions in four key areas.



**CONTINUOUS
IMPROVEMENT**



CYBERSECURITY



SUPPLY CHAIN



**QUALITY
MANAGEMENT**



utahip.org



info@utahip.org



SOLUTION-ORIENTED TRAINING & RESOURCES



LEARN

Through custom-tailored trainings



TRANSFORM

Improve business with a partner dedicated to your success



OPTIMIZE

Operations, processes, efficiency, and profits





JAY MUSE
CEO,
PIPER ACCESS

Jay Muse spent 25 years working at various large companies before leaving to start several medical device startups: Talon Surgical in 2015, Piper Access in 2016, and Slipstream Medical in 2023. He is fascinated with how everything works, and he especially loves the “aha moments” when all the dots connect to create something new and better.



TAYLOR NADAULD
PROFESSOR OF FINANCE,
BYU MARRIOTT SCHOOL OF
BUSINESS

Taylor D. Nadauld is the chair of the Finance Department at BYU and the H. Taylor Peery Professor of Finance. His research focuses on consumer credit and its role in the U.S. economy. He currently serves as an associate editor at the *Journal of Finance*. Outside of his time at BYU, Taylor leads the Research Institute at nCino, a publicly-traded FinTech that provides online banking services for some of the largest financial institutions in the world. He also serves as the chairman of the board for MVP Private Markets Fund, an SEC-registered private equity investment fund. Taylor was also recently named to the Governor’s FinTech Advisory Council in the state of Utah.



BRYCE NELSON
COOPERATIVE EDUCATION
PROGRAM MANAGER,
TALENT READY UTAH

Bryce is facilitating Utah’s first state-wide co-op, working with the Talent Ready Utah team towards the mission of building a highly-skilled workforce while providing students with increased career and education opportunities. She enjoys the challenges presented by designing research-informed programming aligned with the needs of students, industry, and academic stakeholders.




GABRIELE NIEDERAUER, PHD
CEO & CO-FOUNDER,
FREYYA, INC.

Gabriele Niederauer, PhD, FAIMBE, serves as CEO and co-founder of Freyya, her 5th medical device company. Gabi has over 30 years of experience in medical device product development and commercialization and served in key senior management positions. She is an accomplished and highly-engaged executive leader with broad-based experience taking clinical ideas from concept to market to exit. All four of her former companies were acquired: Bluegrass Vascular Technologies – acquired by Merit Medical; ENTrigue Surgical – acquired by ArthroCare, C2M Medical – acquired by Tornier, OsteoBiologics – acquired by Smith & Nephew.



ANDY OLSON
CEO,
PATH FERTILITY

Andy Olson, MBA, is co-founder and CEO of Path Fertility, where he is building a category-defining epigenetic diagnostics platform to transform reproductive health, beginning with male infertility. With 20 years of experience commercializing molecular and DNA-based diagnostics, he has led commercialization in five healthcare startups through scale, achieving four successful exits. Under his leadership, Path Fertility has secured integration into Fortune 500 employer benefits—including Walmart—and is rolling out across leading national fertility networks. Andy holds a BS in Molecular Biology from Brigham Young University and an MBA from the University of Houston’s C.T. Bauer College of Business.



INNOVATION IN DIAGNOSTICS HELPS PRESERVE ANTIBIOTIC EFFICACY FOR FUTURE GENERATIONS

Antimicrobial resistance (AMR) is one of the greatest global health threats of our time—claiming 1.14 million lives every year¹. Together, we have the power to change that.

Pioneering diagnostics empower clinicians to make faster, more informed decisions—reducing antibiotic overuse, improving patient care, and protecting future generations.

Join the effort to advance antimicrobial stewardship, safeguard global health and *help make the world a healthier place.*

1. Global burden of bacterial antimicrobial resistance 1990–2021. *The Lancet* 2024.



MARK OTT, MD
INAUGURAL DEAN,
BRIGHAM YOUNG UNIVERSITY
SCHOOL OF MEDICINE

Mark Ott, MD received his BA in Chemistry and MD degrees from the University of Utah. He completed a surgical residency and surgical oncology fellowship at Johns Hopkins. His surgical, medical education, and administrative career began at MGH in Boston and finished with Intermountain Health in Utah. He has been on the faculty of Johns Hopkins, the Harvard School of Medicine, Stanford, and the University of Utah. He now works to help create the BYU School of Medicine.



SARA PATAK
PARTNER,
WILSON SONSINI GOODRICH
& ROSATI

Sara L. Patak is a partner in the Boulder office of Wilson Sonsini Goodrich & Rosati. Her practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceutical and biotechnology industries. During law school, Sara was an extern for licensing officers in the invention transfer group at UC Irvine Applied Innovation, where she assisted in the drafting and negotiating of university patent licenses and inter-institutional agreements, as well as conducted patentability and marketability assessments for UC Irvine intellectual property. Under the direction of an attorney supervisor, Sara also counseled several pro bono clients in the UC Irvine Intellectual Property, Arts, and Technology Law Clinic relating to copyright, patent, and trademark protection.



MARK PAUL
EXECUTIVE DIRECTOR,
UNIVERSITY OF UTAH
CENTER FOR MEDICAL
INNOVATION

Mark H. Paul is the executive director of the Center for Medical Innovation and advisor for life science incubators for the technology license office at University of Utah Health. He also currently serves on the executive committee of the Utah Innovation Fund, BioUtah immediate past chair & executive committee and other advisory boards. Prior to this role, Mark served 16 years as the global president of the Neurovascular division at Stryker. Stryker Neurovascular is a pioneer and world market leader in the development of technologies for the treatment of Hemorrhagic and Ischemic Stroke. During his tenure the NV division delivered exceptional global growth as the fastest growing division over 12 years achieving \$1.3B in annual revenue. Mark had full P&L responsibilities for all operational functions and commercial teams in +65 countries. Mark is a 32-year veteran of the medical device industry. Mark has led organizations focused on technologies for the less invasive treatment of neurovascular, peripheral vascular & embolization, cardiology, abdominal aortic aneurysms, and carotid intervention.



PAUL PERREAUULT
CONSULTANT, BOARD MEMBER,
SPEAKER, AUTHOR,
STRATEADERSHIP

Paul is a strategic advisor and consultant, mentor, speaker and a published author. He specializes in biotechnology, pharmaceutical, medtech and CDMO companies. He is also an independent board member, chairman of Corden Pharma, board member for Orna Therapeutics and co-founder of Park City Bio. Paul has been in the pharma and biotech ecosystem for over 45 years and previously served as chief executive officer and managing director of CSL limited. Paul led CSL's growth to becoming a world leading biotech company for rare diseases.

INNOVATIVE CONSTRUCTION FOR UTAH'S LIFE SCIENCES.

We are dedicated to providing modern, cost-effective construction solutions to build and support the innovative needs of Utah's life science community.





CHAD POLLARD, PHD
CEO,
RENEW BIOTECHNOLOGIES

Chad Pollard, PhD, earned his degrees in Genetics, Genomics, and Biotechnology (B.S.) and Cell Biology and Physiology (PhD) from Brigham Young University. He is a genomic scientist and biotechnology entrepreneur with expertise in DNA methylation, cell-free DNA biomarkers, and translational genomics. Chad is the co-founder and CEO of Renew Biotechnologies, where he leads the development of multiple clinical and research technologies built on the nanopore sequencing platform. His work spans assay development, bioinformatics, and commercialization, with a focus on turning advanced genomics into scalable, real-world tools.



ANDY ROBERTSON
EXECUTIVE DIRECTOR,
BIOHIVE

Andy Robertson is the executive director of BioHive, Utah's public-private partnership building, branding, and bringing together the state's life sciences ecosystem. A classically trained and award-winning life science marketer, he's known as a cross-functional "Chief of Getting Stuff Done." Andy made his mark at Fortune 100/500 companies to startups, launching over 15 medical devices that generated \$38M in first-year sales. His expertise spans strategy, operations, M&A integration, investor and public relations, fundraising, product management and new product development. A dedicated family man, he also spends an inordinate amount of time honing his mediocre cycling prowess.



BRAD RANDALL
MANAGING PARTNER,
UNION CAPITAL PARTNERS

Brad Randall is managing partner at Union Capital Partners, where he leads investment strategy and portfolio growth initiatives. He also serves as a founding board member of Renew Biotechnologies, supporting the company's strategic development and innovation efforts. Brad holds a Juris Doctor from Arizona Summit School of Law and a degree in Spanish Literature from Arizona State University, bringing a strong legal foundation and international perspective to his work in private equity and cross-border investment.



DANIEL RODRIGUEZ-GRANROSE, PHD
FOUNDER & CEO,
INTACTIS BIO CORP.

Daniel Rodriguez-Granrose, PhD, PSM, is founder, CEO of Intactis Bio Corp. He has assembled and leads an 11-person, cross-disciplinary team advancing living, lab-grown neurons, as a computational substrate. Daniel has 15 years of industry experience across artificial intelligence and tissue engineering, he pioneered AI-driven tissue scale-up methods and invented Intactis Bio's initial bioreactor and culture platform. Under his leadership, the team successfully demonstrated functional biocomputation in living tissues, establishing the technical foundation for the company's next-generation, energy-efficient computing systems.





Access the real price of healthcare



Tired of the same 8–10% renewals every year?
So were we.

Nomi Health delivers a new operating system for self-funded healthcare—connecting payments, analytics, and direct access so you can finally see the real price of healthcare and act on it.

Our solutions

-  **Analytics**
An industry-leading benefits analytics platform that delivers real-time insights to uncover cost drivers, optimize performance, and design smarter, data-backed benefit strategies.
-  **Direct Network**
Direct provider contracts at market-leading rates—members pay \$0 out of pocket while employers gain real savings and simplified access to high-quality care.
-  **Rx Management**
A transparent pharmacy benefit manager that reduces drug costs and provides employers with visibility into pharmacy spend—without restricting member access.
-  **Financial Services**
A modern payment infrastructure built for healthcare. Brings the flexibility and sophistication of fintech to provider payments—giving you full visibility and control.

Nomi by the numbers:

\$200B+


Managed healthcare spend

4.5K+

Employer groups

30M

Lives on platform



Rebuild your healthcare experience with Nomi.

>>> Learn more at nomihealth.com



BRANDEN ROSENHAN, MD
 FOUNDING PARTNER,
 MEDMOUNTAIN VENTURES

Branden Rosenhan, MD, is founder of MedMountain Ventures, a seed healthcare firm focusing on medtech, health IT, digital health, and payor services. A board-certified critical care physician with over 15 years in internal medicine, pediatrics, and critical care, he served as HCA Healthcare’s critical care executive for over a decade. A bioengineer with multiple US patents, he founded PenBlade Inc. (sold to Tidi Products), co-founded ReddyPort Inc. (Chairman), and is a board observer at Epitel Inc. He holds a BS from Arizona State University (magna cum laude) and MD from the University of Utah.



RYAN RUST
 SENIOR DIRECTOR,
 BUSINESS DEVELOPMENT,
 ELI LILLY AND COMPANY

Ryan is a senior director of business development for the Catalyze360 organization at Eli Lilly. In this role, he negotiates collaboration agreements with partners to enable their science to advance from the lab to the clinic. Ryan started at Lilly in 2017 in global and U.S. market access. He successfully executed contracts with top PBMs and health insurance plans in the U.S. and led price strategy development for new drug launches. Ryan obtained a BSc degree in nutrition from Brigham Young university and PharmD and MBA degrees from Butler University.



JUSTIN RUSKO
 SR. ACCOUNT EXECUTIVE,
 MUSA TECHNOLOGY PARTNERS

Justin is a senior account executive at musa Technology Partners, where he works closely with growing companies to align their technology with their long-term business goals. His focus is on building strong, trusted relationships and helping leadership teams think strategically about IT, whether that’s scaling infrastructure, strengthening security, or preparing for compliance milestones like SOC 2. Justin is passionate about simplifying complex technology challenges and turning IT into a true business enabler. He takes pride in being a reliable partner to his clients and an advocate for solutions that drive measurable growth and resilience.



TRAVIS SESSIONS
 FOUNDER & CEO, BIOMERICS /
 MANAGING PARTNER,
 WASATCH HEALTH PARTNERS

Travis Sessions is the founder of Biomerics, a top quartile medical device CDMO and the founder of Wasatch Health Partners, a mid-market MedTech investor.



KAPIL SHARMA
 FOUNDER & CEO,
 VIRA REGEN INC.

Kapil Sharma is founder & CEO of Vira Regen, advancing regenerative medicine through gene-targeted bioelectric stimulation. He brings over a decade of experience in life sciences startup commercialization and bioelectric stimulation research. He is also known for his role at Altitude Lab (Recursion’s startup accelerator) launching 40+ startups in Utah and \$180M+ in seed financing. He holds a BS in Biomedical Engineering, an MS in Bioengineering, and dual MBA and MS in Finance all from the University of Utah.



SUPPLYING THE FIGHT AGAINST CANCER



Next-generation cancer therapies are being held back because critical components – medical radioisotopes – needed for advanced treatments and methods of diagnosis are scarce.

**We need new solutions.
That's where Nusano comes in.**

Nusano's breakthrough technologies and methods are poised to transform the production of medical radioisotopes and help usher in an exciting new era in health care. From our state-of-the-art facility in West Valley City, Utah, Nusano is working to produce medical radioisotopes quickly and efficiently. This will make desperately needed supplies available to researchers and drugmakers around the world, and offer those with life-threatening diseases hope for a healthier tomorrow.

Learn more and see our work:
nusano.com.



JACOB SHEFFIELD
FOUNDER & CEO,
BLOOM SURGICAL

Jacob Sheffield is an entrepreneur, inventor, and engineer specializing in compliant and deployable systems. He has experience founding multiple technology companies and is the founder and CEO of Bloom Surgical, a medical device startup developing technologies to improve visualization and efficiency in minimally invasive surgery. Sheffield has been named one of Utah’s 20 in Their 20s and recognized as BYU’s Entrepreneur and Innovator of the Year. He holds a Master’s degree in Mechanical Engineering from Brigham Young University and is dedicated to creating impactful, next-generation technologies.



CHUCK SPENCE
PROGRAM DIRECTOR,
UTAH APEX ACCELERATOR

Chuck Spence has had a long-distinguished career in public service for the State of Utah. His last 25 years in business and economic development – his passion. Chuck earned his Bachelor’s Degree in Political Science and Master of Public Administration (MPA) from the University of Utah. Chuck was appointed Director of the APEX Accelerator in April 2016, where he provides leadership for a statewide program and a staff of ten employees. Chuck joined the Governor’s Office of Economic Opportunity in February 2005. In October 2022, Chuck was the recipient of the Governor’s Award for Excellence in Leadership by Governor Spencer Cox.



TOMI SMITH
ECOSYSTEM VENTURE PARTNER/
LP OF FUND,
NW ANGEL FUND

Tomi Lynn Smith is a seasoned entrepreneur, strategic operator, and venture ecosystem builder with more than 20 years of experience scaling companies across education, energy, recruiting, and investment platforms. She has built and exited multiple businesses and now serves in leadership roles supporting founders, investors, and portfolio companies in aligning vision with disciplined execution. Tomi specializes in operational infrastructure, partnership-driven revenue models, and preparing companies for financing and long-term growth. Known as a super-connector, she bridges capital and capability—helping founders build scalable organizations while giving investors confidence in the creation of sustainable enterprise value.



CURTIS SPROUSE
CEO, PRESIDENT,
INSTITUTE FOR BIOMEDICAL
ENTREPRENEURSHIP (IBE)
& EUREKACONNECT

Curtis R. Sprouse is a strategic advisor, life sciences entrepreneur, and board director with deep experience across Fortune 500 pharmaceutical, biotech, and healthcare sectors. He specializes in guiding early- and mid-stage companies through growth, capital formation, and technical proof of concept toward successful investor exits. A serial founder, Curtis has launched and scaled multiple ventures, advised hundreds of biomedical innovations from bench to bedside, and supported blockbuster product launches. He combines market strategy, behavioral dynamics, and governance expertise to build high-performing teams and scalable business models.

DIGITAL HEALTH INITIATIVE

DEVELOPING DIGITAL INNOVATIONS TO IMPROVE HEALTH

The Digital Health Initiative (DHI) aims to transform health and health care for patients, their families, and their health care teams by cultivating a thriving research community of **digital healthcare pioneers**.

DRIVING FORWARD DIGITAL HEALTH RESEARCH BY:

Developing digital health innovations:



- + mobile apps & games for health
- + virtual reality and sensors
- + integration with electronic health records

Investigating these innovations' effects on quality and value of care:




- + real-world pragmatic trials
- + regulatory guidance (e.g., FDA)
- + commercialization pipeline
- + co-designing with the community

THE DELPHI DATA SCIENCE INITIATIVE

DATA EXPLORATION AND LEARNING FOR PRECISION HEALTH INTELLIGENCE

Biomedical data science integrates large, complex data sets with innovative computational approaches to create actionable insights across biological and medical applications. The **DELPHI** data science initiative aims to drive innovation in health and medicine by catalyzing biomedical data science research



Sign up for our newsletter to learn more



DHI



DELPHI



HEALTH
UNIVERSITY OF UTAH



MICHAEL STARK, PHD
ASSOCIATE DEAN,
COLLEGE OF LIFE SCIENCES
BRIGHAM YOUNG UNIVERSITY

Michael Stark is a professor in the Department of Cell Biology & Physiology at BYU, where he served as chair before accepting his current position as associate dean of research in the College of Life Sciences. He received his PhD from UC Irvine and was a postdoctoral trainee at the University of Utah before joining the faculty at BYU. Most of his research has focused on gene regulation in early vertebrate nervous system development, but has shifted his work to study gene regulation in fibrosis, including idiopathic pulmonary fibrosis. He recently co-founded OvaSci, a Utah-based biotech startup company.



ADAM STEVENS
TECHNOLOGY LICENSING
PROFESSIONAL,
BRIGHAM YOUNG UNIVERSITY

Received degrees in biomedical engineering and English, with an emphasis on electrical engineering. Attended law school and became a patent attorney, practicing at Kirton McConkie for 16 years, helping clients obtain patents and trademarks for a variety of technologies, including spinal implants, catheters, and hospital evacuation devices. Joined BYU's Technology Transfer Office in 2023, being the first patent attorney to work in the office, bringing that legal technical experience to benefit the office and the College of Life Sciences particularly. Looks forward to opening of the BYU Medical School and the opportunities for collaboration that will result.



CLIFFORD STEELE
CEO,
DIGIBEAT HEALTH
MONITORING

Clifford Steele brings aerospace engineering precision, med-tech innovation, and entrepreneurial leadership to DigiBeat. At Philips Healthcare, he led development of 12 MRI systems from design through 510(k), commercialization, and production. As founder of ApexTek, he raised capital, built an R&D lab, and launched 31 patented products into ecommerce and retail. Inspired by a personal loss to heart disease, Cliff founded DigiBeat to deliver hospital-grade cardiac monitoring at home. As CEO, he pairs engineering excellence with bold vision to expand access to life-saving cardiac technology worldwide.



IZI STOLL, PHD
FOUNDER & CEO,
NUMIERA THERAPEUTICS

Izi Stoll earned her PhD in Neurobiology and Behavior from the University of Washington, completed postdoctoral research at the Wellcome Trust Centre for Mitochondrial Research, then started her own laboratory at Newcastle University, leading research teams to develop targeted small-molecule therapies for cancer and lentiviral-based gene therapies for epilepsy. Now, as scientific director of the Western Institute for Advanced Study, she leads interdisciplinary teams to tackle the organization's Grand Challenges, and as CEO of Numiera Therapeutics, she is leading on the clinical development of a first-in-class target in cancer cell metabolism.

THANK YOU BIOUTAH

For Elevating Life Sciences Globally



CONTENT
CARNIVORES



GABI TELLEZ
INVESTOR,
SPRINGTIDE VENTURES

Gabi Tellez has spent her career at the intersection of healthcare startups, policy, and investing – having held roles at Leavitt Partners, Intermountain Ventures, Utah Innovation Fund (Now Nucleus Fund), and SpringTide Ventures. She is especially passionate about the consumerization of health care.



RYAN WATTS, PHD
CEO,
DENALI THERAPEUTICS

Ryan Watts is the CEO of Denali Therapeutics. He is a co-founder, president, and a member of the Board of Directors. Denali has advanced multiple therapeutic candidates into clinical testing for Lysosomal Storage Diseases and common neurodegenerative diseases. Denali has invented a proprietary blood-brain barrier platform for delivery of therapeutic proteins to the brain. Ryan previously served as director of the Department of Neuroscience at Genentech. Ryan obtained his PhD from Stanford University’s Department of Biological Sciences and his BS in Biology from the University of Utah.



BRANDON WEBB, MD
ASSOCIATE DEAN FOR
RESEARCH,
BRIGHAM YOUNG UNIVERSITY
SCHOOL OF MEDICINE

Brandon Webb, MD, is an infectious disease-trained physician-investigator and associate dean of research for the BYU School of Medicine. Dr. Webb’s clinical practice specializes on infections in immunocompromised patients and emerging global threats. His research uses predictive modeling to focus diagnostics and treatment on high-risk populations and on applying implementation science and pragmatic clinical research methods to generate real-world evidence and improve outcomes.



KRISTIN WIHERA
DIRECTOR OF FUND
OPERATIONS,
NUCLEUS INSTITUTE

Kristin Wihera currently works as the director of fund operations at Nucleus Institute. She leads the day-to-day operations of Nucleus Fund, a \$40M state-backed venture fund focused on early-stage deep tech innovation in Utah. She brings a breadth of experience in defense, energy, biotechnology, and investing. Kristin previously served as a naval officer in the US Navy. During her service, she led sailors in ship operations, naval nuclear propulsion, and the Navy Wounded Warrior program. Kristin holds an MBA and an MS in Biotechnology, both from Harvard University, and a BS in Human Physiology from Boston University.



RUDY WILCOX
CTO, CO-FOUNDER
REFLODX, INC.

With over 15 years experience in the medical device space, Rudy Wilcox has founded multiple startups and currently serve as the CTO of RefloDx, Inc. Previously, he oversaw the R&D division at Blackrock Microsystems, and was the lead engineer on multiple devices that were released into the animal research and clinical electrophysiology space. Rudy holds a BS in Computer Engineering from Brigham Young University and a MS in Bioengineering from the University of Utah.



JASON YOUNG
DIRECTOR OF
COMMERCIALIZATION,
UNIVERSITY OF UTAH
TECHNOLOGY LICENSING OFFICE

Jason manages a portfolio of life science technologies that includes therapeutics, medical devices, and digital health technologies. He uses his entrepreneurial and clinical experience to help researchers understand potential market opportunities, protect their ideas through IP management, and develop commercial partnerships to advance their technologies.



AZUNIC
JERRY HENLEY, CEO
AZUNIC.COM

Full IND preclinical readiness FDA package without sacrificing one animal.



BLOOM SURGICAL
JACOB SHEFFIELD, CEO
BLOOMSURGICAL.COM

Bloom Surgical is revolutionizing laparoscopic surgery with LaparoVision, a novel origami-inspired “windshield wiper” for laparoscopes.



DIGIBEAT
CLIFFORD STEELE, CEO
DIGIBEAT.HEALTH

DigiBeat has simplified the operation of cardiac screening to the point that medical assistance, and even at-home patients, can operate it.



FREYYA, INC.
GABRIELE NIEDERAUER,
CEO & CO-FOUNDER
FREYYA.COM

Freyya is a femtech medical device company transforming pelvic floor care for the 1 in 4 women living with pelvic floor disorders.



GLAFABRA
CHRIS HOPKINS, CEO
GLAFABRA.COM

Glafabra’s Live-cel™ gene therapy provides patients with a highly effective and redosable treatment.



INTACTIS BIO
DANIEL RODRIGUEZ-GRANROSE,
FOUNDER & CEO
INTACTIS.BIO

Intactis Bio offers biocomputation as a service to the AI/ML industry for low-energy computation, with true biological intelligence.



MICROVASCULAR THERAPEUTICS
EMMANUELLE MEUILLET, PHD, CSO
MVTPHARMA.COM

MVT is a clinical-stage biotech advancing microbubble and nanobubble tech for ultrasound.



MYXTEK BIO
CHRISTIAN IVERSON, CO-FOUNDER
MYXTEKBIO.COM

MyxTek Bio is a next-generation biomaterials company commercializing USU’s patented hagfish protein technology to create high-performance protein membranes.



NUMIERA THERAPEUTICS
IZI STOLL, FOUNDER & CEO
NUMIERA.COM

Numiera Therapeutics is developing small-molecule drugs for oncology indications by targeting a key metabolic vulnerability in cancer cells.



PATH FERTILITY
ANDY OLSON, CEO
PATHFERTILITY.COM

At Path Fertility, we built SpermQT: the first clinically validated epigenetic sperm quality test.



PURGO SCIENTIFIC
NICHOLAS ASHTON, CTO
PURGOSCIENTIFIC.COM

Purgo Scientific is developing a first-in-class refillable drug delivery device called the Purgo Pouch that sustains local, high-dose antibiotic therapy in surgical sites.



UV SENSE
KRISTINA SCHIFFMAN
UVSENSE.US

UV Sense develops systems for continuous measurement and analysis of ultraviolet (UV) exposure.

stryker

We improve lives

**Customers and patients are at
the heart of everything we do.**

We're a driven company where
people work with passion, purpose
and integrity to deliver remarkable,
innovative products for customers
and patients.

**Find out more about how
you can make a difference
at careers.stryker.com**





PITCH HALL COMPANIES

FIND MORE INFORMATION IN WHOVA

TITLE SPONSOR

**WILSON
SONSINI**

FOR MORE DETAILS ABOUT THESE COMPANIES, PLEASE VISIT THE PITCH HALL IN THE WHOVA APP USED TO FACILITATE AND SUPPORT THIS SUMMIT.

AC THERATECH

SONYA SONG

AC TheraTech operates an AI-powered preventive health engine to assess early health risks, deliver personalized prevention strategies, and recommend evidence-based ingredients and products.

AGED DIAGNOSTICS*

RACHEL ZAYAS

AGED Diagnostics is developing the first accurate, noninvasive blood test to diagnose MASH and stage liver fibrosis.

ALLELERX THERAPEUTICS, INC.

MARISA BROTHWELL

We are a seed stage gene therapy company targeting rare genetic conditions. Our mission is to develop safe and transformative molecular therapies for Congenital Disorders of Glycosylation with expansion to other genetic diseases.

ANZIVA PHARMACEUTICALS INC.

SIMERDEEP SINGH GUPTA

Anziva Pharmaceuticals Inc. is a preclinical drug delivery company focused on non-opioid pain management through advanced transdermal patch technologies.

CALYCIA BIOSCIENCE

DANIEL GREINER

CaLycia Bioscience is a preclinical biotechnology developing a novel cell therapy platform designed to leverage the unique characteristics of myeloid cells.

DIAGNOSTIC VENTURES

BRIAN BENTLEY

Diagnostic Ventures is revolutionizing Sepsis diagnostics with a patented spinning disk technology & Raman Spectroscopy w/AI delivers sepsis identification results in 20 minutes.

ePURINES, INC

BK KISHORE

ePurines is focused on developing innovative purinergic signaling-based and orally active small molecules drugs for the prevention/treatment of obesity and metabolic syndrome, and primary diseases of the kidney, liver, and heart.

EUTHYMIC STUDIOS

JEFF CLARK

Euthymic Studios builds effective, irresistibly fun software that improves health. Our first product is Slumber Quest: a game that walks users through all the skills needed to reverse real-life insomnia.

EYESCREEN

ZIA L'ECUYER

Eyescreen is revolutionizing preclinical drug development for ophthalmology by bridging the critical gap between traditional animal models and human clinical trials.

FOLDSIGHT BIO

LOCKE HANSEN

FoldSight Bio diagnoses patients with amyloid diseases faster and earlier than any other method. Using a prick of patient's blood we can diagnose diseases in our lab-developed test.

HOMEWATCH CAREGIVERS OF McDONOUGH

ERICA McCRAE

Homewatch CareGivers of McDonough is a Georgia-based home care provider dedicated to helping seniors, veterans, and adults remain safely and comfortably at home.

iMEDISYNC

REBEKAH WALKER

Brain health screenings are stuck in the past—messy gels, wires, and long hospital wait times. iMediSync, has solved this with iSyncWave - a wireless device to combine AI brain mapping and LED Therapy in a single headset.

INDEL BIOINNOVATIONS

PEYTON JACKSON

Indel Bioinnovations is a biopharmaceutical company developing a restorative gene therapy for triple-negative breast cancer.

ISOBODIES

DIMITRI TRAENKNER

IsoBodies makes the invisible visible. Most genes produce multiple protein isoforms, and when their balance breaks, disease follows—from autism to cancer.

KYPHOLIFT*

BRANDON JOHNSON

KyphoLift develops diagnostic medical imaging solutions built from front-line clinical experience. The company addresses a systemic MRI workflow and safety gap.



MEDICAL TIMESERIES NETWORKS (MTN)

WARREN PETTINE

MTN makes diverse real-time health data actionable so care teams can provide faster, better care. This addresses critical problems like throughput and provider burnout.

NARA THERAPY

PEREZ WILLIE-NWOBU

Nara Therapy combines therapy with AI and personalized self-care tools that boost outcomes from 52% - 83% helping providers manage, monitor, and support their clients.

ORTHOBOLT

BRANDON WILDE

OrthoBolt has designed an expandable screw optimized with cutting-edge rotating strut technology. These screws offer optimal anchoring in both healthy and compromised bone.

OVASCI

MARC HANSEN

Ovasci uses its transgenic chicken to mass produce high value recombinant proteins in the egg.

PANOROMICS HEALTH SCIENCES, LLC.

JEREMY TIAN

Panoromics is an early-stage biotech startup with a focus on identifying personalized health risks and mitigating them through cost-effective, holistic approaches.

PILLR.

ISAAC NIELSEN

Pillr is a med-tech startup dedicated to solving medication security, non-adherence, and verification. Our Pillr Cadence device is a smart pill dispenser that combines secure fingerprint authentication with weight verification.

PRESSURE MEDICAL INC.

RYAN HOGAN

Pressure Medical develops next-generation smart pneumatic tourniquets that save lives. Our patented technology delivers precise, automatic pressure regulation to control severe bleeding.

REFLODX, INC.

GREGORY CRITCHFIELD

RefloDx is a medical device company developing SondeFlux, a non-invasive at-home monitoring technology to work up the 15M-25M individuals seeking medical evaluation each year in the U.S. for chronic voice and throat complaints.

SNOW CANYON THERAPEUTICS

DAVID BLACKWELL

Snow Canyon Therapeutics develops NRF2-activating small molecules to treat degenerative diseases, including ALS, Retinitis Pigmentosa, and Friedreich's Ataxia.

TESA RESEARCH

SOHEIL SHAMS

TESA Research is an early-stage biotechnology company with the mission to improve clinical trial outcomes and reduce failure of targeted cancer therapies.

TRIOVANCE

IAN WISENBERG

Triovance is a clinical-stage biotechnology company developing a novel therapeutic approach to improve healing in chronic wounds.

VIRA REGEN INC.

KAPIL SHARMA

Initially funded by the US Department of War, Vira Regen is a developer of gene-specific bioelectronic medicines designed to accelerate bone fracture healing, musculoskeletal injuries, osteoarthritis/osteoporosis, and bone cancer.

** These companies were selected as alternates should one of the presenting companies drop out for any reason.*



UNDERSTAND. INNOVATE. DELIVER.

Merit Medical's mission is to be the world's most customer-focused healthcare company by understanding customers' needs and innovating and delivering a diverse range of products that improve the lives of people, families, and communities throughout the world.

**FOUNDED
IN 1987**

- // Global Headquarters in South Jordan, Utah
- // 9 Manufacturing Locations Worldwide
- // 7,100 Employees
- // MMSI \$3.6B Market Cap



Merit Vascular / Merit Spine / Merit Oncology / Merit Endoscopy

merit.com/careers



SUMMIT EXHIBITORS

TITLE SPONSOR
**WILSON
SONSINI**

VISIT THE BOOTH OF THE EXHIBITORS LISTED BELOW



CHECK OUT THE VIRTUAL BOOTHS OF OUR ONLINE EXHIBITORS

In addition to our on-site exhibitors, please visit our virtual exhibit hall that includes many of our on-site exhibitors as well.



Use this QR code to view the virtual exhibitors.

BALLARD GOES BEYOND

Our life sciences lawyers assist entrepreneurs, investors, and companies at all stages in achieving their objectives as they move from innovation to commercialization and beyond. We are proud to support the 2026 Entrepreneur & Investor Life Sciences Summit and to sponsor the Life Sciences Ski Day.

CONTACTS

Scott D. Marty, Ph.D.

Co-Leader, Life Sciences Industry Team

martys@ballardspahr.com

Ryan J. Udell

Co-Leader, Life Sciences Industry Team

udellr@ballardspahr.com

**Ballard
Spahr**
LLP

ATTORNEY ADVERTISING



ELITE MEMBERS

TITLE SPONSOR
**WILSON
SONSINI**

LEGACY MEMBERS



PLATINUM MEMBERS



GOLD MEMBERS



SILVER MEMBERS



BRONZE MEMBERS





Doing work today, for all your tomorrows

Wherever care happens, BD will be there. Just as it has done for more than 125 years, BD remains committed to innovating and delivering impactful solutions and services for healthcare professionals whenever they need it, and wherever care is delivered.

Visit [bd.com](https://www.bd.com) to learn more.



BD

Advancing the
world of health™

Welcome to the
world, bestie.



Intermountain
Health

The Power of **We**